Analysts Offer Predictions for InflaRx FY2026 Earnings

InflaRx (NASDAQ:IFRX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for InflaRx in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price objective on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share.

A number of other equities analysts have also weighed in on IFRX. Oppenheimer dropped their price objective on InflaRx from $6.00 to $3.00 and set an "outperform" rating for the company in a research note on Thursday, May 29th. Raymond James cut InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target on the stock. in a report on Thursday, May 29th. HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st. Finally, Guggenheim lifted their price objective on shares of InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $6.60.

InflaRx Stock Down 2.0%

IFRX stock traded down $0.02 during trading on Tuesday, reaching $0.78. The company's stock had a trading volume of 819,458 shares, compared to its average volume of 283,348. The company's fifty day moving average is $1.28 and its 200-day moving average is $1.75. The company has a market capitalization of $52.63 million, a P/E ratio of -0.73 and a beta of 1.29. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new stake in shares of InflaRx in the fourth quarter worth about $28,000. Cubist Systematic Strategies LLC increased its stake in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after acquiring an additional 7,616 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of InflaRx during the 1st quarter worth approximately $38,000. Walleye Capital LLC bought a new position in shares of InflaRx during the 4th quarter valued at approximately $51,000. Finally, Geode Capital Management LLC boosted its position in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after acquiring an additional 11,900 shares during the last quarter. Hedge funds and other institutional investors own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.